登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>HGF R >CHEK-ATF144

Human c-MET (Luc) HEK293 Reporter Cell

For research use only.

描述(Description)

The Human c-MET (Luc) HEK293 Reporter Cell was engineered to express signaling response element driving luciferase expressing systems and human c-MET (Gene ID: 4233). When stimulated with human HGF protein, the HGF/c-MET interaction drives RE-mediated luminescence. Neutralization of biological effect of human HGF protein by corresponding antibody results in a decrease in luminescence.

应用说明(Application)

• Screen for neutralizing antibodies blocking the stimulation of human HGF protein.

HGF R Assay Principles

生长特性(Growth Properties)

Adherent

筛选标记(Selection Marker)

Puromycin (2 μg/mL)

培养基(Culture Medium)

DMEM + 10% FBS

冻存液(Freeze Medium)

Serum-free cell cryopreservation medium

装量(Quantity)

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

 

Receptor Assay

HGF R FACS

Expression analysis of human c-MET on Human c-MET (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human c-MET (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-human c-MET antibody.

Protocol

 

Application

HGF R APPLICATION

Inhibition of human HGF protein-induced reporter activity by anti-human c-MET neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human HGF protein with a final concentration of 0.3 μg/mL. The EC50 of anti-human c-MET neutralizing antibody (Amivantamab) is approximately 0.07699 μg/mL.

Protocol

 

Signaling Bioassay

HGF R SIGNALING

Response to human HGF protein (RLU).
This reporter cell was incubated with serial dilutions of human HGF protein. The EC50 was approximately 0.1506 μg/Ml.

Protocol

HGF R SIGNALING

Response to human HGF protein (FOLD).
This reporter cell was incubated with serial dilutions of human HGF protein. The max induction fold was approximately 41.75.

Protocol

如有相关细胞池需求请联系我们

 

背景(Background)

Hepatocyte growth factor receptor (HGFR) is also known as mesenchymal-epithelial transition factor (MET), c-Met, and is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. HGFR protein possesses tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. HGFR is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymal origin. Upon HGF stimulation, HGFR induces several biological responses that collectively give rise to a program known as invasive growth. Abnormal HGFR activation in cancer correlates with poor prognosis, where aberrantly active HGFR triggers tumor growth, formation of new blood vessels (angiogenesis) that supply the tumor with nutrients, and cancer spread to other organs (metastasis). HGFR is deregulated in many types of human malignancies, including cancers of kidney, liver, stomach, breast, and brain. Normally, only stem cells and progenitor cells express HGFR, However, cancer stem cells are thought to hijack the ability of normal stem cells to express HGFR, and thus become the cause of cancer persistence and spread to other sites in the body. Various mutations in the HGFR gene are associated with papillary renal carcinoma. HGFR mediates a complex program known as invasive growth. Activation of HGFR triggers mitogenesis, and morphogenesis.

 

Permits & Restrictions

This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
HGF R靶点信息
英文全称:Hepatocyte growth factor receptor
中文全称:肝细胞生长因子受体
种类:Homo sapiens
上市药物数量:9详情
临床药物数量:61详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定